-
BDP9066
- names:
BDP9066
- CAS号:
2226507-04-4
MDL Number: - MF(分子式): C20H24N6 MW(分子量): 348.44
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM004333-100mg | 100mg | >97% | ¥ 0.00 | ¥ 0.00 | Get quote | ¥ 0.00 | ||
| YZM004333-5mg | 5mg | >97% | ¥ 9800.00 | ¥ 9800.00 | 2-3weeks | ¥ 0.00 | ||
| YZM004333-1mg | 1mg | >97% | ¥ 3520.00 | ¥ 3520.00 | 2-3weeks | ¥ 0.00 |
| 中文别名 | BDP9066; BDP-9066; BDP 9066 |
| 英文别名 | (S)-8-(3-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1,8-diazaspiro[5.5]undecane |
| CAS号 | 2226507-04-4 |
| Inchi | InChI=1S/C20H24N6/c1-2-8-25-20(6-1)7-3-11-26(13-20)17-5-10-22-19-18(17)15(12-23-19)16-4-9-21-14-24-16/h4-5,9-10,12,14,25H,1-3,6-8,11,13H2,(H,22,23)/t20-/m0/s1 |
| InchiKey | UELSMLDRSQFVHG-FQEVSTJZSA-N |
| 分子式 Formula | C20H24N6 |
| 分子量 Molecular Weight | 348.44 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | -20°C 12 Months; 4°C 6 Months |
BDP9066(CAS:2226507-04-4)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | BDP9066 为肌强直性肌营养不良相关 Cdc-42 结合激酶MRCK的选择性有效抑制剂,其在 SCC12 细胞中测得对 MRCKβ 的IC50值为 64 nM,对 MRCKα/β 的Ki值分别为 0.0136 nM 和 0.0233 nM |
| Introduction | BDP9066 is a potent and selective myotonic dystrophyelated Cdc42inding kinaseMRCKinhibitor with anIC50of 64 nM for MRCKβ in SCC12 cells,Kivalues of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation. |
| Application1 | BDP9066是有效的选择性MRCK抑制剂,可减少底物的磷酸化, BDP9066导致癌细胞的形态变化以及对它们的运动性和侵袭性的进行抑制。 |
| Application2 | |
| Application3 |
BDP9066(BDP-9066)是一种强效且选择性强直性肌营养不良症相关的Cdc42结合激酶MRCK抑制剂,IC50为43 nM,选择性比相关ROCK1或ROCK2高100倍,BDP9066 通过降低底物磷酸化来治疗皮肤癌。
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinaseMRCKinhibitor with anIC50of 64 nM for MRCKβ in SCC12 cells,Kivalues of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
BDP9066(BDP-9066)是一种强效且选择性强直性肌营养不良症相关的Cdc42结合激酶MRCK抑制剂,IC50为43 nM,选择性比相关ROCK1或ROCK2高100倍; 对MRCKα和MRCKβ具有相似的活性; 抑制MLC2磷酸化(EC50 = 64 nM)并阻止SCC12鳞状细胞癌的运动性和侵袭性; 减少鼠鳞状细胞癌化学致癌模型中的MRCKαS1003自磷酸化和皮肤乳头状瘤生长。
BDP9066 (BDP-9066) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM, >100-fold selectivity over related ROCK1 or ROCK2; shows similar activity against MRCKα and MRCKβ; inhibits MLC2 phosphorylation (EC50=64 nM) and blocks SCC12 squamous cell carcinoma motility and invasion; reduces MRCKα S1003 autophosphorylation and skin papilloma outgrowth in chemical carcinogenesis model of murine squamous cell carcinoma.
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinaseMRCKinhibitor with anIC50of 64 nM for MRCKβ in SCC12 cells,Kivalues of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
BDP9066(BDP-9066)是一种强效且选择性强直性肌营养不良症相关的Cdc42结合激酶MRCK抑制剂,IC50为43 nM,选择性比相关ROCK1或ROCK2高100倍; 对MRCKα和MRCKβ具有相似的活性; 抑制MLC2磷酸化(EC50 = 64 nM)并阻止SCC12鳞状细胞癌的运动性和侵袭性; 减少鼠鳞状细胞癌化学致癌模型中的MRCKαS1003自磷酸化和皮肤乳头状瘤生长。
BDP9066 (BDP-9066) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM, >100-fold selectivity over related ROCK1 or ROCK2; shows similar activity against MRCKα and MRCKβ; inhibits MLC2 phosphorylation (EC50=64 nM) and blocks SCC12 squamous cell carcinoma motility and invasion; reduces MRCKα S1003 autophosphorylation and skin papilloma outgrowth in chemical carcinogenesis model of murine squamous cell carcinoma.
| 1. Unbekandt M, et al. Cancer Res. 2018 Apr 15;78(8):2096-2114. |
【1】.Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114.
【2】.Unbekandt M, Belshaw S, Bower J, Clarke M, Cordes J, Crighton D, Croft DR, Drysdale MJ, Garnett MJ, Gill K, Gray C, Greenhalgh DA, Hall JAM, Konczal J, Lilla S, McArthur D, McConnell P, McDonald L, McGarry L, McKinnon H, McMenemy C, Mezna M, Morrice NA, Munro J, Naylor G, Rath N, Schüttelkopf AW, Sime M, Olson MF. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114. doi: 10.1158/0008-5472.CAN-17-2870. Epub 2018 Jan 30. PubMed PMID: 29382705; PubMed Central PMCID: PMC5901721.
【2】.Unbekandt M, Belshaw S, Bower J, Clarke M, Cordes J, Crighton D, Croft DR, Drysdale MJ, Garnett MJ, Gill K, Gray C, Greenhalgh DA, Hall JAM, Konczal J, Lilla S, McArthur D, McConnell P, McDonald L, McGarry L, McKinnon H, McMenemy C, Mezna M, Morrice NA, Munro J, Naylor G, Rath N, Schüttelkopf AW, Sime M, Olson MF. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114. doi: 10.1158/0008-5472.CAN-17-2870. Epub 2018 Jan 30. PubMed PMID: 29382705; PubMed Central PMCID: PMC5901721.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


